Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alger Small Cap Focus Fund Amy Zhang | “Exact Sciences is a molecular diagnostics company focused on oncology testing, best known for its Cologuard noninvasive colorectal cancer screening franchise, alongside a broader portfolio and pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing initiatives. Shares contributed positively during the quarter after Abbott announced a definitive all-cash agreement to acquire Exact Sciences for approximately $21 billion in equity value, reflecting a meaningful premium and driving the stock higher. BSD Analysis: Exact Sciences built its franchise on Cologuard, turning non-invasive cancer screening into a mainstream clinical tool. The long-term opportunity lies in expanding beyond colorectal cancer into multi-cancer screening and blood-based diagnostics. Revenue growth remains solid, but profitability is still constrained by heavy R&D and commercialization spend. The company's clinical credibility and payer coverage create real barriers to entry. Execution risk centers on converting scientific promise into scalable, reimbursed products. If operating leverage finally kicks in, earnings power changes quickly. This is a diagnostics platform still transitioning from growth story to business discipline.” | BULL | Q4 2025 Jan 8, 2026 | View Pitch |
The Gabelli ABC Fund Mario J. Gabelli, CFA, Willis Brucker | “Exact Sciences Corp. (4.5% of net assets as of December 31, 2025), is a provider of cancer screening and diagnostic services. The company continues to expand adoption of its non-invasive colorectal cancer screening platform while investing in additional oncology diagnostics. We believe the long-term growth opportunity in early cancer detection remains substantial given low screening penetration rates. Operational execution and reimbursement progress are key drivers of value creation. The position reflects our view that strategic interest in the oncology diagnostics space remains robust. BSD Analysis: Exact Sciences built its franchise on non-invasive cancer screening, turning prevention into recurring diagnostics revenue. Cologuard remains the anchor product, though competition is rising. Growth depends on physician adoption and payer coverage expansion. R&D spend is heavy because pipeline credibility matters. Profitability remains a work in progress. Data depth and brand recognition provide some moat. This is not a quick-profit diagnostics story. It's a long-duration bet on screening behavior becoming standard. Exact works if scale finally translates into sustainable margins.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Baron Discovery Fund Randy Gwirtzman | “Shares of Exact Sciences Corporation contributed to performance. Exact is a molecular diagnostics company focused on the early detection of colorectal cancer. It is best known for its non-invasive colorectal cancer screening stool test called Cologuard. The big picture is that half of the 106 million adults in the U.S. recommended for colorectal cancer screening are not up to date, and we think the Cologuard test presents the best combination of non-invasiveness and accurate sensitivity/specificity as compared to more invasive colonoscopies and less accurate blood tests. Exact shares outperformed in 2025 as the restructuring of the commercial team drove Cologuard volume growth reacceleration, and shares further outperformed as Abbott Laboratories announced an agreement to acquire Exact Sciences for $23 billion in November. The deal represents a greater than 50% premium over the prior closing price. BSD Analysis: Exact Sciences is diagnostics infrastructure built around early cancer detection, not a one-product story. Cologuard established the beachhead, but the real value is in expanding screening into blood-based and multi-cancer assays. Investors fixate on reimbursement debates and margin pressure and miss how sticky guideline-driven diagnostics become once adopted. Primary care workflow integration matters more than flashy sensitivity stats. Cash burn dominates sentiment, but scale changes the unit economics fast in diagnostics. Competition is real, yet switching tests at the population level is slow and political. This is a long-cycle healthcare platform obscured by quarterly noise.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Exact Sciences Corp. is a cancer diagnostics company best known for Cologuard, its at-home screening test for colorectal cancer. The stock initially rose during the quarter on signs of reinvigorated growth and the introduction of a new test that drove revenue higher. Performance was further boosted when Abbott announced plans to acquire Exact Sciences at a significant premium. BSD Analysis: Exact Sciences sits at the intersection of diagnostics, screening compliance, and payer economics. Non-invasive cancer screening expands the funnel rather than cannibalizing procedures. Adoption depends on guideline support and physician workflows, not consumer marketing. Investors worry about losses and long commercialization timelines. Yet scale improves gross margins meaningfully over time. Pipeline extensions broaden relevance beyond colorectal cancer. Regulatory and reimbursement moats matter more than brand. This is diagnostics infrastructure playing the long game.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
